CN113730553A - anti-HPV (human papillomavirus) gel dressing and preparation method thereof - Google Patents
anti-HPV (human papillomavirus) gel dressing and preparation method thereof Download PDFInfo
- Publication number
- CN113730553A CN113730553A CN202110759566.2A CN202110759566A CN113730553A CN 113730553 A CN113730553 A CN 113730553A CN 202110759566 A CN202110759566 A CN 202110759566A CN 113730553 A CN113730553 A CN 113730553A
- Authority
- CN
- China
- Prior art keywords
- parts
- container
- gel
- mass
- hpv virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000701806 Human papillomavirus Species 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 45
- 239000002904 solvent Substances 0.000 claims abstract description 23
- 239000004615 ingredient Substances 0.000 claims abstract description 16
- 241000700605 Viruses Species 0.000 claims description 45
- 239000000499 gel Substances 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 102000014150 Interferons Human genes 0.000 claims description 16
- 108010050904 Interferons Proteins 0.000 claims description 16
- 229940079322 interferon Drugs 0.000 claims description 16
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 15
- 235000013824 polyphenols Nutrition 0.000 claims description 15
- 229910052711 selenium Inorganic materials 0.000 claims description 15
- 239000011669 selenium Substances 0.000 claims description 15
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 14
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 14
- 241001122767 Theaceae Species 0.000 claims description 14
- 229940089161 ginsenoside Drugs 0.000 claims description 14
- 229930182494 ginsenoside Natural products 0.000 claims description 14
- 229940068041 phytic acid Drugs 0.000 claims description 14
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 14
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 13
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 9
- 229960001631 carbomer Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241001474374 Blennius Species 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 42
- 230000000694 effects Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 201000010153 skin papilloma Diseases 0.000 description 4
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229960002751 imiquimod Drugs 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical group C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 2
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydroxyl polyphenols Chemical class 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof, belonging to the technical field of medicines, wherein the anti-HPV gel dressing comprises anti-HPV powder, a powder solvent and gel ingredients, and the preparation method of the anti-HPV gel dressing comprises the preparation of the powder solvent, the dissolution of the HPV gel dressing and the preparation of the gel dressing.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof.
Background
Human papillomavirus (HPV virus), a papillomavirus a genus belonging to the papovaviridae family, is a spherical DNA virus that causes squamous epithelial proliferation of the human skin mucosa. It is manifested by symptoms such as common wart and genital wart (condyloma acuminatum). With the rapid increase of the incidence rate of condyloma acuminatum in venereal diseases and the increase of cervical cancer, anal cancer and the like, HPV virus infection is attracting more and more attention. At present, no ideal method can completely eliminate HPV virus in a therapeutic operation, so that the main method for resisting HPV virus mainly comprises treatment, medicine and autoimmune resistance.
At present, the medicines for resisting HPV virus mainly comprise a-type interferon and imiquimod cream, the a-type interferon is used as an antiviral agent and can promote cells to generate antiviral protein so as to inhibit the proliferation of HPV virus, but the use of the a-type interferon has side effects of fever nausea, bone marrow inhibition, leucocyte reduction and the like, the imiquimod cream is an immunomodulator and has slow effect taking time, a user can take the medicine for at least 4-16 weeks to initially take effect, but the imiquimod cream has certain irritation, and the skin is easy to have shallow erosion face after long-term use.
The simple HPV infection does not need to be treated, only the HPV induces cervical CIN lesion or outgrows warts, the warts need to be treated, most of HPV can be removed after the surgical treatment, but the organism also contains a small amount of HPV, at the moment, the body constitution is enhanced through dressing, the immunity of the human body is improved, and the HPV can be automatically removed by the immunity of the human body.
Disclosure of Invention
The invention aims to provide an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof, and aims to solve the problem that the existing anti-HPV application medicine proposed in the background art is easy to have side effects.
In order to achieve the purpose, the invention provides the following technical scheme: the anti-HPV virus gel dressing comprises anti-HPV virus powder, a powder solvent and a gel ingredient, wherein the anti-HPV virus powder comprises 2-5 parts by mass of ginsenoside, 2-3 parts by mass of tea polyphenol, 6-9 parts by mass of inositol hexaphosphate, 1-2 parts by mass of interferon, 2-4 parts by mass of seaweed selenium and 1-3 parts by mass of chlorhexidine gluconate, the powder solvent comprises 70-80 parts by mass of normal saline, 10-20 parts by mass of glycerol and 5-8 parts by mass of ethanol, the gel ingredient comprises 1-2 parts by mass of carbomer, 0-2 parts by mass of sodium hydroxide, 0-5 parts by mass of triethanolamine, 40-60 parts by mass of polysaccharide and 1-2 parts by mass of silica gel micropowder, and the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 2-3: 1-2.
Preferably, the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 2:1.
Preferably, the anti-HPV virus powder comprises, by mass, 4-5 parts of ginsenoside, 2 parts of tea polyphenol, 8-9 parts of inositol hexaphosphate, 2 parts of interferon, 3-4 parts of selenium alga and 2-3 parts of chlorhexidine gluconate.
Preferably, the powder solvent comprises 70-75 parts by weight of normal saline, 15-20 parts by weight of glycerol and 5-6 parts by weight of ethanol.
Preferably, the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 3:2.
Preferably, the anti-HPV virus powder comprises, by mass, 2-3 parts of ginsenoside, 3 parts of tea polyphenol, 6-7 parts of inositol hexaphosphate, 1 part of interferon, 2 parts of seaweed selenium and 1-2 parts of chlorhexidine gluconate.
Preferably, the powder solvent comprises 75-80 parts by weight of normal saline, 10-15 parts by weight of glycerol and 7-8 parts by weight of ethanol.
A preparation method of an anti-HPV virus gel dressing comprises the following steps:
the method comprises the following steps: pouring normal saline into a first container and a second container, adding glycerol and ethanol into the first container, uniformly stirring, and sequentially adding chlorhexidine gluconate, selenium alga, tea polyphenol, interferon and inositol hexaphosphate into the first container;
step two: adding carbomer into a container B, stirring, simultaneously dropwise adding sodium hydroxide into the container B, ensuring that the pH in the container B is kept at 5-7, detecting the pH in the container B after the carbomer is added, and adding triethanolamine into the container B when the pH is 5-6 until the pH in the container B reaches 6-7;
step three: adding the liquid in the container B into the container A, stirring, adding triethanolamine into the container A after uniformly stirring, adjusting the pH value in the container A to 7-8, adding ginsenoside and silica gel micropowder into the container A, and stirring;
step four: slowly adding polysaccharide into the container A, stirring until the liquid in the container A becomes gel, then continuously stirring for 10-12 min, and then extruding the gel in the container A and packaging to obtain the anti-HPV virus gel dressing.
Preferably, step three is to filter the liquid in the first container by using a 2um filter screen and retain the liquid after finishing.
Compared with the prior art, the invention has the beneficial effects that:
in the invention, the ginsenoside can enhance the cellular immune mechanism of a human body, the tea polyphenol is used for assisting HPV to quickly turn negative, the inositol hexaphosphate can be effectively matched with HPV protein molecules, so that the conversion rate of the HPV to the protein is reduced, the alga selenium can enhance the biological self-regulation effect, regulate the human body autoimmunity and avoid the cellular dissimilation.
Drawings
FIG. 1 is a table showing the negative change after administration of the present invention;
FIG. 2 is a table of the present invention showing recurrence after administration of the drug of FIG. 1;
FIG. 3 is a table showing the negative change after administration of the present invention;
FIG. 4 is a table of the relapse after administration of the drug of FIG. 3 according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the description of the present invention, it is to be understood that the terms "upper", "lower", "front", "rear", "left", "right", "top", "bottom", "inner", "outer", and the like, indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, are merely for convenience in describing the present invention and simplifying the description, and do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, should not be construed as limiting the present invention.
In the description of the present invention, it should be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "disposed," "sleeved/connected," "connected," and the like are to be construed broadly, e.g., "connected," which may be fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in specific cases to those skilled in the art.
Referring to fig. 1-4, the present invention provides a technical solution: an anti-HPV virus gel dressing comprises anti-HPV virus powder, powder solvent and gel ingredients, and is characterized in that: the anti-HPV virus powder comprises 2-5 parts of ginsenoside, 2-3 parts of tea polyphenol, 6-9 parts of inositol hexaphosphate, 1-2 parts of interferon, 2-4 parts of alga selenium and 1-3 parts of chlorhexidine gluconate, wherein the ginsenoside is ginsenoside Rb2 and Rh2, the ginsenoside Rh2 has the functions of transferring pathological cells, enhancing organism immunity and recovering physique, the ginsenoside Rb2 has the function of reducing cell calcification so as to avoid the regeneration of warts, the tea polyphenol contains more than 2 ortho hydroxyl polyphenols, has stronger hydrogen supply capacity and can assist in accelerating the conversion of HPV virus to negative, cations in the inositol hexaphosphate can be effectively matched with anionic protein molecules in the HPV virus so as to reduce the conversion rate of the HPV virus to proteins, the interferon is an efficient antiviral bioactive substance and has a wide immune regulation function, selenium alga can enhance the biological self-regulation effect, regulate the human body autoimmunity, avoid cellular dissimilation, chlorhexidine gluconate can be mutually dissolved with water, alcohol and glycerol, the property is stable, the selenium alga is a good antibacterial agent, a powder solvent comprises 70-80 parts of normal saline, 10-20 parts of glycerol and 5-8 parts of ethanol by mass, a gel ingredient comprises 1-2 parts of carbomer, 0-2 parts of sodium hydroxide, 0-5 parts of triethanolamine, 40-60 parts of polysaccharide and 1-2 parts of superfine silica gel by mass, and the mass ratio of the HPV virus resistant powder, the powder solvent and the gel ingredient is 2: 2-3: 1-2.
A preparation method of an anti-HPV virus gel dressing comprises the following steps:
the method comprises the following steps: pouring normal saline into a first container and a second container, adding glycerol and ethanol into the first container, uniformly stirring, and sequentially adding chlorhexidine gluconate, selenium alga, tea polyphenol, interferon and inositol hexaphosphate into the first container;
step two: adding carbomer into a container B, stirring, simultaneously dropwise adding sodium hydroxide into the container B, ensuring that the pH in the container B is kept at 5-7, detecting the pH in the container B after the carbomer is added, and adding triethanolamine into the container B when the pH is 5-6 until the pH in the container B reaches 6-7;
step three: adding the liquid in the container B into the container A, stirring, adding triethanolamine into the container A after uniformly stirring, adjusting the pH value in the container A to 7-8, adding ginsenoside and silica gel micropowder into the container A, and stirring;
step four: slowly adding polysaccharide into the container A, stirring until the liquid in the container A becomes gel, then continuously stirring for 10-12 min, and then extruding the gel in the container A and packaging to obtain the anti-HPV virus gel dressing.
And step three, filtering the liquid in the first container by using a 2um filter screen and retaining the liquid after finishing.
Example 1:
the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 2:1.
The anti-HPV virus powder comprises, by mass, 4-5 parts of ginsenoside, 2 parts of tea polyphenol, 8-9 parts of inositol hexaphosphate, 2 parts of interferon, 3-4 parts of seaweed selenium and 2-3 parts of chlorhexidine gluconate.
The powder solvent comprises 70-75 parts by mass of normal saline, 15-20 parts by mass of glycerol and 5-6 parts by mass of ethanol.
And (3) test results: referring to fig. 1 and 2, test group 1, test group 2, test group 3 and control group 1 are all applied after surgery, test group 4 and control group 2 are both directly applied, test group 1 and test group 4 are applied 1 time a day, test group 2 is applied 2 times a day, test group 3 is applied 3 times a day, control group 1 and control group 2 are applied 2 times a day with traditional anti-HPV gel dressing, test group 1, 2, 3 and 4 are all the prescriptions in example 1, 10 healing personnel are selected from each group after 20 weeks to participate in the reexamination, and all the healing personnel participate in the reexamination to stop applying the medicine.
Example 2:
the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 3:2.
The anti-HPV virus powder comprises, by mass, 2-3 parts of ginsenoside, 3 parts of tea polyphenol, 6-7 parts of inositol hexaphosphate, 1 part of interferon, 2 parts of seaweed selenium and 1-2 parts of chlorhexidine gluconate.
The powder solvent comprises 75-80 parts by mass of normal saline, 10-15 parts by mass of glycerol and 7-8 parts by mass of ethanol.
And (3) test results: referring to fig. 3 and 4, the test group 55, the test group 6, the test group 7 and the control group 3 are all applied after surgery, the test group 8 and the control group 4 are both directly applied, the test group 5 and the test group 8 are applied 1 time a day, the test group 6 is applied 2 times a day, the test group 7 is applied 3 times a day, the control group 3 and the control group 4 are respectively applied 2 times a day with traditional anti-HPV gel dressing, the test groups 5, 6, 7 and 8 are all the prescriptions in the example 2, 10 healing personnel are selected from each group after 20 weeks for reexamination, and all the recovery personnel stop applying the medicine.
While there have been shown and described the fundamental principles and essential features of the invention and advantages thereof, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing exemplary embodiments, but is capable of other specific forms without departing from the spirit or essential characteristics thereof; the present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein, and any reference signs in the claims are not intended to be construed as limiting the claim concerned.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. An anti-HPV virus gel dressing comprises anti-HPV virus powder, powder solvent and gel ingredients, and is characterized in that: the anti-HPV virus powder comprises, by mass, 2-5 parts of ginsenoside, 2-3 parts of tea polyphenol, 6-9 parts of inositol hexaphosphate, 1-2 parts of interferon, 2-4 parts of selenium alga and 1-3 parts of chlorhexidine gluconate, the powder solvent comprises, by mass, 70-80 parts of normal saline, 10-20 parts of glycerol and 5-8 parts of ethanol, the gel ingredient comprises, by mass, 1-2 parts of carbomer, 0-2 parts of sodium hydroxide, 0-5 parts of triethanolamine, 40-60 parts of polysaccharide and 1-2 parts of micropowder silica gel, and the ratio of the anti-HPV virus powder to the powder solvent to the gel ingredient is 2: 2-3: 1-2.
2. The anti-HPV virus gel dressing according to claim 1, characterized in that: the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 2:1.
3. An anti-HPV viral gel dressing according to claim 2, characterized in that: the anti-HPV virus powder comprises, by mass, 4-5 parts of ginsenoside, 2 parts of tea polyphenol, 8-9 parts of inositol hexaphosphate, 2 parts of interferon, 3-4 parts of seaweed selenium and 2-3 parts of chlorhexidine gluconate.
4. An anti-HPV viral gel dressing according to claim 2, characterized in that: the powder solvent comprises 70-75 parts by mass of normal saline, 15-20 parts by mass of glycerol and 5-6 parts by mass of ethanol.
5. The anti-HPV virus gel dressing according to claim 1, characterized in that: the mass ratio of the anti-HPV virus powder, the powder solvent and the gel ingredient is 2: 3:2.
6. An anti-HPV virus gel dressing according to claim 5 characterised in that: the anti-HPV virus powder comprises, by mass, 2-3 parts of ginsenoside, 3 parts of tea polyphenol, 6-7 parts of inositol hexaphosphate, 1 part of interferon, 2 parts of seaweed selenium and 1-2 parts of chlorhexidine gluconate.
7. An anti-HPV virus gel dressing according to claim 5 characterised in that: the powder solvent comprises 75-80 parts by mass of normal saline, 10-15 parts by mass of glycerol and 7-8 parts by mass of ethanol.
8. A method of preparing an anti-HPV virus gel dressing according to any one of claims 1-7, characterized in that: the preparation method of the anti-HPV virus gel dressing comprises the following steps:
the method comprises the following steps: pouring normal saline into a first container and a second container, adding glycerol and ethanol into the first container, uniformly stirring, and sequentially adding chlorhexidine gluconate, selenium alga, tea polyphenol, interferon and inositol hexaphosphate into the first container;
step two: adding carbomer into a container B, stirring, simultaneously dropwise adding sodium hydroxide into the container B, ensuring that the pH in the container B is kept at 5-7, detecting the pH in the container B after the carbomer is added, and adding triethanolamine into the container B when the pH is 5-6 until the pH in the container B reaches 6-7;
step three: adding the liquid in the container B into the container A, stirring, adding triethanolamine into the container A after uniformly stirring, adjusting the pH value in the container A to 7-8, adding ginsenoside and silica gel micropowder into the container A, and stirring;
step four: slowly adding polysaccharide into the container A, stirring until the liquid in the container A becomes gel, then continuously stirring for 10-12 min, and then extruding the gel in the container A and packaging to obtain the anti-HPV virus gel dressing.
9. The method for preparing an anti-HPV virus gel dressing according to claim 8, wherein the method comprises the following steps: and step three, filtering the liquid in the first container by using a 2um filter screen and retaining the liquid after finishing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110759566.2A CN113730553A (en) | 2021-07-06 | 2021-07-06 | anti-HPV (human papillomavirus) gel dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110759566.2A CN113730553A (en) | 2021-07-06 | 2021-07-06 | anti-HPV (human papillomavirus) gel dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113730553A true CN113730553A (en) | 2021-12-03 |
Family
ID=78728621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110759566.2A Pending CN113730553A (en) | 2021-07-06 | 2021-07-06 | anti-HPV (human papillomavirus) gel dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113730553A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919871A (en) * | 2010-08-10 | 2010-12-22 | 黄波 | Application of cyclophosphamide and panaxoside in preparing medicine for treating condyloma acuminatum |
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| CN104491838A (en) * | 2014-12-19 | 2015-04-08 | 海南森瑞谱生命科学药业股份有限公司 | Anti-HPV (human papillomavirus) gel dressing and preparation method thereof |
| CN106177911A (en) * | 2016-08-31 | 2016-12-07 | 易金阳 | A kind of biological composition dressing of prophylactic treatment HPV infection |
| CN110478514A (en) * | 2019-06-18 | 2019-11-22 | 广西信业生物技术有限公司 | A kind of anti-HPV viruse dressing and preparation method thereof |
| CN112089841A (en) * | 2020-04-05 | 2020-12-18 | 徐静 | Pharmaceutical composition for treating diseases caused by virus infection of epithelial tissues |
-
2021
- 2021-07-06 CN CN202110759566.2A patent/CN113730553A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| CN101919871A (en) * | 2010-08-10 | 2010-12-22 | 黄波 | Application of cyclophosphamide and panaxoside in preparing medicine for treating condyloma acuminatum |
| CN104491838A (en) * | 2014-12-19 | 2015-04-08 | 海南森瑞谱生命科学药业股份有限公司 | Anti-HPV (human papillomavirus) gel dressing and preparation method thereof |
| CN106177911A (en) * | 2016-08-31 | 2016-12-07 | 易金阳 | A kind of biological composition dressing of prophylactic treatment HPV infection |
| CN110478514A (en) * | 2019-06-18 | 2019-11-22 | 广西信业生物技术有限公司 | A kind of anti-HPV viruse dressing and preparation method thereof |
| CN112089841A (en) * | 2020-04-05 | 2020-12-18 | 徐静 | Pharmaceutical composition for treating diseases caused by virus infection of epithelial tissues |
Non-Patent Citations (2)
| Title |
|---|
| 王滨 等: "植酸酮治疗HPV感染合并CIN I期的临床疗效观察", 国际妇产科学杂志, vol. 39, no. 5, pages 536 * |
| 蔡虹 等: "感染HPV的宫颈组织微量元素硒检测及其相关研究", 中国热带医学, vol. 8, no. 8, pages 1315 - 1316 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008628B (en) | Medicament for treating female genital tract virus infection and preparation method of sustained-release preparation of medicament | |
| KR20130130573A (en) | Composition effective for alleviating atopic dermatitis containing mixture of seamustard sporophyll and ascidian tunic extract | |
| JP7196192B2 (en) | Chinese herbal medicine composition, Chinese herbal medicine formulation and its preparation method and application | |
| CN113730553A (en) | anti-HPV (human papillomavirus) gel dressing and preparation method thereof | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN102988603A (en) | Wolfberry polysaccharide granules | |
| CN102295683B (en) | Anti-herpes simplex virus polypeptide and its application | |
| CN103191163B (en) | Skin wound repairing pharmaceutical composition | |
| CN106177900A (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN102688330B (en) | Biological Chinese medicine film and preparation method thereof | |
| WO2011103794A1 (en) | Spray for treating diseases caused by human papilloma virus and preparation method thereof | |
| CN105663684A (en) | Medicine for treating aplastic anemia | |
| CN101375955B (en) | Sperm-passing formulation for treating non-ejaculation symptom and preparation method thereof | |
| CN105031382A (en) | Traditional Chinese medicine preparation for treating gallbladder polyps and preparation method thereof | |
| CN116270940B (en) | Traditional Chinese medicine composition for preventing and treating HPV virus infection as well as preparation method and application thereof | |
| CN100464753C (en) | foscarnet sodium composition | |
| CN110025705A (en) | A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis | |
| CN1742951A (en) | Health-care preparation for reducing blood-fat and raising human-body immunity | |
| CN102512359B (en) | Mangiferin cream with anti-herpes virus effect | |
| CN112220739B (en) | HPV virus inactivation dressing and preparation method thereof | |
| CN113440574B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating viral myocarditis | |
| CN101375971B (en) | Rejuvenating and yang-invigorating formulation for treating yin deficiency type impotence and preparation method thereof | |
| CN1111055C (en) | Ichthyosis treating cream and its preparation | |
| Sibiak et al. | Recent findings on perinatal mesenchymal stem cells–their possible application in current advanced medicine | |
| CN106822524B (en) | Compound medicine for treating infertility and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |